Rapamycin-nanoliposomes and senescence in rat nucleus pulposus cells
In this abstract, rapamycin-nanoliposomes inhibited mTORC1 and reduced senescence features of nucleus pulposus cells in cell experiments; in rats with IL-1β-induced disc degeneration, imaging and histology indicated less degeneration. [1]
Automatic summary · not editorially reviewed
The key findings
Rapamycin-nanoliposomes suppressed senescence-related features of nucleus pulposus cells in cell experiments. [1]
The authors report that the particles inhibited mTORC1, blocked the NLRP3/Caspase-1 pathway and activated the autophagy-lysosomal pathway. [1]
In rats with IL-1β-induced disc degeneration, imaging and histology indicated that the injected particles mitigated degeneration. [1]
The source at a glance
- Study type / format
- Preclinical in vitro and rat in vivo study (abstract)
- Population / context
- Nucleus pulposus cells and rats with IL-1β-induced intervertebral disc degeneration
- Summary based on
- Study abstract
- Original publication
- August 3, 2026
Rapamycin-nanoliposomes tested on NP cell senescence
The abstract describes rapamycin-nanoliposomes made by ultrasonic dispersion, thin-film dispersion and filtration to improve rapamycin bioavailability. In cell experiments, they suppressed senescence-related features of nucleus pulposus cells: morphological changes, higher IL-1β/TNF-α secretion, increased β-gal activity, lysosomal dysfunction, upregulated P21/P16 and reduced P27. The authors report that the particles targeted and inhibited mTORC1, then blocked the NLRP3/Caspase-1 pathway and activated the autophagy-lysosomal pathway to maintain cell quiescence.
Supporting source [1]
Rat disc degeneration after IL-1β induction
In vivo, the rapamycin-nanoliposomes were injected into rat intervertebral discs with degeneration induced by IL-1β. X-ray, MRI and histological evaluation confirmed that the treatment mitigated intervertebral disc degeneration, according to the abstract. The authors conclude that the particles act via mTORC1-mediated NLRP3/Caspase-1 and autophagy-lysosomal pathways to inhibit nucleus pulposus cell senescence, and call this a promising strategy for prevention of disc degeneration.
Supporting source [1]
Abstract-only scope of the rapa-lipos evidence
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports cell experiments and a rat model but gives no sample sizes, follow-up durations or effect sizes, and the prevention framing is the authors' interpretation. The findings are preclinical and do not show that rapamycin-nanoliposomes prevent disc degeneration or affect aging in humans.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No sample sizes, follow-up durations or effect sizes are reported. Findings are preclinical (cells and rats) and do not establish human benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Xing H, Yu M, Liu J, Zhao R, Ai X, Tang R, Zhu T, Li Y, Jiang L, Wei Q, Huang Y, Guo Y, Jiang T, Huang B. · europepmc.org · August 3, 2026